Diverse Discovery at an Exponential Pace
X-Chem’s DNA-encoded library (DEL) technology and medicinal chemistry expertise take small molecule discovery to another level. Along with the ability to screen billions of compounds rapidly, our proprietary methods enable you to screen against difficult and previously “undruggable” targets.
Highly Optimized
Recent advances in these difficult classes point to previously unattainable possibilities for drug development. From PPI research to bispecific molecules. From covalents to novel GPCR antagonists, the future is bright. Whatever your modality, X-Chem can help put your novel therapy on the path to clinic.
Our highly optimized small molecule screening approach has successfully delivered hit compounds against a host of target class applications:
Protein-protein interactions are a traditionally challenging but emerging target class for therapeutic drug design. Their large, flat surfaces present difficulties for small molecule screening, but X-Chem’s powerful DEL technology leverages billions of compounds to make expedited PPI discovery an area of strength.
TPD requires linkage of molecule fragments; DEL technology provides that linker. TPD is opening new doors in drug development, and X-Chem’s DEL is the perfect tool for any modality in this space. Molecular glues induce protein association without the need for chimeric molecules. Only the very largest libraries and efficient selection methods can uncover such rare and valuable compounds.
Innovation is built into every solution at X-Chem, and our scientists have demonstrated this foundational tenet through the powerful pairing of our platform and covalent inhibitor libraries. We invented covalent DEL, and our DELvalent service puts the world’s leading covalent screening method and all the possibilities of this modality within your grasp.
Kinases are a well-explored target class and the bread and butter of many drug discovery programs. Yet, unexplored territory remains… this is where X-Chem shines. With the structural novelty of our vast library and tunable selection methods, we can discover selective, pan-, and allosteric inhibitors for your kinase of interest.
GPCRs are a well-validated target class but can be difficult for biophysical screening methods. Using our DEL technology and massive libraries, we have identified potent hits that bind GPCRs. With billions of compounds available to screen, X-Chem can power the success of your GPCR discovery campaign.
Proven Capabilities Applied to Your Project
X-Chem’s track record of leading DNA-encoded library-based discovery for over a decade is well-documented. We have delivered validated hits in 30+ target classes across numerous therapeutic areas, and we’re just getting started. Pioneer the future of drug discovery with the experts
at X-Chem.
